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Abstract 
There is a plethora of disease ontologies available, 
all potentially useful for the annotation of biological 
datasets. We define seven desirable features for such 
ontologies and examine whether or not these features 
are supported by eleven disease ontologies. The four 
ontologies most closely aligned with our desiderata 
are Disease Ontology, SNOMED CT, NCI thesaurus 
and UMLS. 
Introduction 
Ontologies have been developed for the annotation of 
biological datasets from multiple perspectives includ-
ing functional annotation of gene products (Gene On-
tology), molecular sequences (Sequence ontology) 
and phenotypes (Mammalian Phenotype Ontology, 
Phenotypic Quality Ontology). Entries in biological 
datasets also need to be linked to diseases, either hu-
man diseases or experimental models of diseases in 
model organisms. Ontologies of diseases include the 
Disease Ontology (DO), from the Open Biomedical 
Ontology (OBO) family. The NCI Thesaurus was de-
veloped for the annotation of cancer research and in-
cludes many diseases, but its focus on cancer can be a 
limitation for use in other domains. 
On the other hand, terminologies have been long been 
developed for the purpose of annotating clinical 
records, including the International Classification of 
Diseases (ICD) and SNOMED CT. However, these 
terminologies have not been widely adopted by bio-
medical researchers for annotating disease entities in 
biological datasets. Moreover, neither terminology is 
free of intellectual property restrictions and a license 
or fee may be required for their use, which represents 
a limiting factor. 
Finally, terminology integration resources such the 
Unified Medical Language System (UMLS) Metathe-
saurus and NCBO’s BioPortal both integrate more 
than one hundred biomedical terminologies, including 
all those mentioned above. Moreover, both resources 
provide mappings across terminologies, facilitating 
the integration of biological and clinical data required 
for translational medicine. However, their use may 
necessitate significant training. 
The objective of this study is to propose a list of de-
sirable features for an ontology of diseases suitable 
for the annotation of biological datasets, and to ana-
lyze a list of candidate terminologies through the 
framework provided by these features. 
Desiderata for selecting ontologies have been estab-
lished by the OBO Foundry1. While interesting and 
potentially relevant to the domain of diseases, we find 
some of these criteria unnecessarily restrictive for the 
purpose of annotating biological datasets, while key 
criteria (from our specific perspective) are missing. A 
brief analysis of the OBO Foundry criteria in the con-
text of our study is proposed in the discussion. 
This work also differs from Cimino’s desiderata for 
controlled medical vocabularies2 in that we focus on 
content and usability for a particular purpose in addi-
tion to representation issues and development 
process. 
Methods  
We first select a list of biomedical terminologies and 
ontologies (hereafter referred to simply as ontologies) 
potentially suitable for the annotation of diseases in 
biological datasets. We establish a list of characteris-
tics from these ontologies, focusing on those charac-
teristics which represent potential barriers to adoption 
of these terminologies by biomedical researchers. We 
apply the list of features to each candidate ontology 
and summarize our findings in a feature x ontology 
matrix. 
Candidate ontologies 
In order to identify candidate ontologies for diseases, 
we explored the two major repositories of biomedical 
ontologies: The Unified Medical Language System 
(UMLS) and NCBO’s BioPortal. We investigated on-
tologies whose focus is on human diseases and phe-
notypes, as well as ontologies which contain a signifi-
cant number of disease entities. In practice, we ex-
ploited the metadata provided with OBO ontologies 
and selected those ontologies for which the domain is 
contains “phenotype” or “health”. No similar mechan-
ism is available for the UMLS and we simply used 
our knowledge of the source vocabularies to make 
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our selection. References to the ontologies discussed 
below are listed in Table 1. This selection process led 
to the identification of eleven ontologies potentially 
suitable for the annotation of diseases in biological 
datasets. 
• Disease Ontology (DO): Controlled terminology 
from the OBO family created for annotation pur-
poses as part of the NuGene project at Northwes-
tern University. Coverage restricted to diseases. 
• Online Mandelian Inheritance in Man 
(OMIM): Knowledge base on human genetic dis-
eases developed at John Hopkins University and 
available through the NCBI Entrez system. Its 
terminological component – including clinical 
synopses – is available through the UMLS. Cov-
erage restricted to genetic diseases. 
• International Classification of Diseases (ICD): 
Classification from the World Health Organiza-
tion (WHO) family of health classifications, with 
many local adaptations. ICD9-CM, developed by 
the Center for Medicare & Medicaid Services 
(CMS) for use in the US, includes clinical modifi-
cations. Coverage restricted to diseases and health 
problems. 
• SNOMED CT: The largest clinical terminology 
developed by the International Health Terminolo-
gy Standard Development Organization 
(IHTSDO) for use in electronic health records and 
adopted by eleven countries to date. Broad cover-
age including diseases. 
• Medical Subject Headings (MeSH): Controlled 
vocabulary developed by the U.S. National Li-
brary of Medicine for the indexing and retrieval of 
the biomedical literature, especially in the 
MEDLINE bibliographic database. Broad cover-
age including diseases. 
• NCI Thesaurus (NCIt): Controlled vocabulary 
developed by the National Cancer Institute to sup-
port the integration of information related to can-
cer research. Broad coverage including diseases. 
• Unified Medical Language System (UMLS): 
Terminology integration system developed by the 
U.S. National Library of Medicine, establishing a 
correspondence among terms from different ter-
minologies for a given biomedical entity. Broad 
coverage including diseases. 
• Human Phenotype Ontology (HPO): Controlled 
vocabulary for the phenotypic features encoun-
tered in human hereditary and other diseases. De-
veloped by a consortium including Charite Hos-
pital (Berlin) and the University of Cambridge 
(UK). Coverage restricted to monogenic diseases 
listed in OMIM. 
• Phenotypic Quality Ontology (PATO): Ontolo-
gy of phenotypic qualities, intended for use in a 
number of applications, primarily defining com-
posite phenotypes and phenotype annotation. 
Coverage restricted to phenotypes. 
• Mammalian Phenotype Ontology: Controlled 
vocabulary for the “robust annotation of mamma-
lian phenotypes” currently used for the annotation 
of phenotypic data in mouse and rat databases. 
Developed at the Jackson Laboratory. Coverage 
restricted to phenotypes. 
• Logical Observation Identifiers Names and 
Codes (LOINC): Set of names and codes for la-
boratory and other clinical observations (elements 
of clinical phenotypes). Developed at the Regen-
strief Institute. Coverage restricted to clinical ob-
servations. 
Phenotype ontologies for organisms other than Homo 
sapiens were ignored. (e.g., Yeast phenotypes). On-
tologies of diseases included as part of a broader on-
tology were ignored when they were unlikely to pro-
vide additional coverage or characteristics useful for 
the discussion in this paper (e.g., National Drug File 
Reference Terminology and International Classifi-
cation of Primary Care). Specialized resources 
(e.g., Online Congenital Multiple Anomaly/Mental 
Retardation Syndromes, Infectious Disease Ontol-
ogy and Diagnostic and Statistical Manual of Men-
tal Disorders), while providing deep coverage of a 
narrow subdomain of medicine, are unlikely to pro-
vide the broad coverage expected from an ontology of 
diseases and were ignored. 
Desirable features 
Starting from the ten OBO Foundry principles, we 
have identified seven desirable features for an ontol-
ogy of diseases. In each case, the absence of a feature 
represents a potential barrier to the adoption of a 
biomedical ontology for the annotation of diseases in 
biological datasets. Differences with the set of OBO 
Foundry principles are discussed later in this paper. 
• No intellectual property restrictions. The use of 
some vocabularies is limited to certain contexts 
(e.g., restriction for research purposes vs. produc-
tion systems for some vocabularies in the UMLS) 
or to certain countries (e.g., member countries of 
the IHTSDO for SNOMED CT), or subject to the 
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payment of a fee (e.g., ICD 10). This feature is 
aligned with Foundry principle #1. 
• Standard, friendly format. Availability of termi-
nologies in formats that are standard (e.g., RDF, 
OWL) or friendly to biologists (e.g., OBO) is like-
ly to foster adoption. In contrast, proprietary for-
mats (e.g., RRF for the UMLS Metathesaurus) 
may represent a barrier to adoption. This feature 
corresponds roughly to Foundry principle #2. 
• Existence of a mapping to clinical terminolo-
gies. In the era of translational medicine, biologi-
cal datasets must be linkable to clinical datasets. 
The existence of mappings between an ontology 
of diseases used for the annotation of biological 
datasets and clinical terminologies used in patient 
records is strong requirement. 
• Harmonization with other biological ontolo-
gies. Similarly to the requirement for integration 
with clinical terminologies, there is a need for a 
disease ontology to be integrated – if possible na-
tively – with other biological ontologies. This fea-
ture corresponds roughly to Foundry principle #5. 
• Regular maintenance. The domain of diseases is 
in constant evolution and an ontology of disease 
shall reflect emerging diseases and changes in our 
understanding of the domain of diseases. This fea-
ture corresponds roughly to Foundry principle #4. 
• Exhaustive coverage of diseases. At a given lev-
el of granularity, the ontology shall provide an ex-
haustive coverage of the domain. Terminologies 
focusing on a specific subdomain may have li-
mited applicability outside this subdomain (e.g., 
focus on cancer in NCIt). 
• Support for automatic reasoning. Annotations 
made to ontologies often form the basis for gain-
ing new knowledge about biomedical entities. In 
order to process annotations efficiently and auto-
matically, ontologies need to have a robust, formal 
structure and provide support for automated rea-
soning (e.g., through subsumption). 
A framework for comparing disease ontologies 
The desirable features listed above do not all have the 
same importance from the perspective of an ontology 
of diseases for annotation purposes. For example, 
coverage of diseases it of the outmost importance for 
an ontology of diseases and was given the highest 
weight (5). Interoperability with other ontologies 
(clinical and biological) and support for automatic 
reasoning correspond to major uses of ontologies and 
are also weighted more (2) than the remaining fea-
tures (1). 
We examined the eleven candidate ontologies 
through the prism of the seven desirable features. 
More precisely, for each feature, we rated the ontolo-
gy semi-quantitatively: 0 (no or minimal support for 
the feature), 0.5 (partial support of the feature) or 1 
(reasonable support for the feature), assessed by the 
authors. The weights were applied to the ratings. Fi-
nally, the score of each ontology was computed by 
comparing the sum of the scores for each feature to 
the sum of all weights (14). 
Results 
The result of assessing the presence of the desirable 
features in the candidate ontologies is summarized in 
Figure 1. Support for the desirable features ranges 
from 32% (OMIM, LOINC) to 68% (NCIt, UMLS). 
Seven ontologies have a score of 50% or more. 
Discussion 
Applying the desiderata. The top four contenders 
identified in our matrix of desirable features x ontol-
ogies (Figure 1) are Disease Ontology, SNOMED 
CT, NCIt and UMLS. Interestingly, these four ontol-
ogies made it to the top for slightly different reasons. 
Depending on what features are most important in a 
given use case, the ontologies corresponding to this 
profile of features should be selected. 
Phenotypes vs. diseases. Precisely defining pheno-
type and disease is beyond the scope of this paper. 
However, we observed that phenotype ontologies 
containing pre-coordinated concepts (e.g., Mamma-
lian Phenotype Ontology, LOINC) or supporting 
post-coordination (e.g., the Phenotypic Quality On-
tology - PATO), cover low-level phenotypes and 
clinical observations (e.g., individual anatomical and 
physiological abnormalities) rather than diseases. Ex-
amples of phenotypes form MPO include enlarged 
liver, found in ontologies including MeSH, NCTt and 
SNOMED CT. In contrast, they mostly contain terms 
indicating deviation from normal anatomical struc-
tures or physiologic states (e.g., decreased liver 
weight), typically absent from the clinically-oriented 
disease ontologies. Phenotype ontologies seem suita-
ble for the annotation of data with low-level pheno-
types, whereas disease ontologies have application in 
the annotation of higher-order information about dis-
eases, i.e., resulting from some elaborate diagnostic 
process. 
Differences with OBO Foundry criteria. Although 
some of our desirable features are aligned with prin-
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ciples of the OBO Foundry1, we found the Foundry 
principles to be generally too rigid for the purpose of 
annotating biological datasets and lacking considera-
tion for legacy ontologies. Applying these principles 
strictly to the selection of ontologies would potential-
ly result in unnecessarily excluding from considera-
tion the datasets annotated to these legacy ontologies. 
Many legacy disease ontologies are not available in 
OWL or OBO format, but are widely used. Borrow-
ing from “orthogonal” ontologies is a good principle 
for the coordinated development of ontologies (i.e., 
applied in a prospective manner). However, this prin-
ciple can hardly be held against legacy disease ontol-
ogies. The absence of textual definition is a common 
feature to many legacy disease ontologies. It can be 
offset in part by the presence of formal definitions (in 
description logic-based systems) and usage informa-
tion. Finally, most widely used disease ontologies are 
developed outside the OBO Foundry and not always 
in a collaborative manner. 
Limitations. The framework provided here for ana-
lyzing disease ontologies is relatively coarse and 
somewhat arbitrary. The list of desirable features and 
the weights would need to be adapted to specific an-
notation scenarios. For example, the presence of syn-
onyms is required if annotations are to be discovered 
automatically in text corpora using text mining tech-
niques. 
Conclusions 
The plethora of disease ontologies available to bio-
medical researchers for annotation purposes is not 
necessarily good news. In this domain in particular, 
reusing existing ontologies should be carefully consi-
dered before starting the development of a new one. 
Annotations made to different ontologies, including 
legacy ontologies, will likely need to be reconciled in 
order to enable interoperability among datasets, 
which is a strong requirement for translational medi-
cine. Terminology integration systems such as the 
UMLS are thus expected to play a key role in data in-
tegration tasks. 
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Table 1. List of potential disease ontologies discussed in this paper 
DO Disease Ontology - http://diseaseontology.sourceforge.net/ 
OMIM Online Mandelian Inheritance in Man - http://www.ncbi.nlm.nih.gov/omim/  
ICD International Classification of Diseases - http://www.who.int/classifications/icd/en/ 
SNOMED CT SNOMED CT - http://www.ihtsdo.org/ 
MeSH Medical Subject Headings - http://www.nlm.nih.gov/mesh/ 
NCI Thes. NCI Thesaurus - http://cancer.gov/cancerinfo/terminologyresources/ 
UMLS Unified Medical Language System - http://www.nlm.nih.gov/research/umls/ 
HPO Human Phenotype Ontology - http://www.human-phenotype-ontology.org/index.php/hpo_home.html 
PATO Phenotypic Quality Ontology - http://www.bioontology.org/wiki/index.php/PATO:Main_Page 
MPO Dictionary of Medicines and Devices - http://www.informatics.jax.org/searches/MP_form.shtml 
LOINC Logical Observation Identifiers Names and Codes - http://loinc.org 
 
 
Figure 1. Desiderata applied to candidate disease ontologies (matrix of desirable features x ontologies) 
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